| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Mothers against decapentaplegic homolog 1;MAD homolog 1;Mothers against DPP homolog 1;JV4-1;Mad-related protein 1;SMAD family member 1;SMAD 1;Smad1;hSMAD1;Transforming growth factor-beta-signaling protein 1;BSP-1;SMAD1;BSP1, MADH1, MADR1; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A synthesized peptide derived from human Smad1 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-Smad1 Rabbit Monoclonal Antibody is an antibody targeting SMAD1. Common applications include WB, ICC, IF. Key specifications include host: Rabbit; clonality: Monoclonal; clone: Clone: CAC-19; isotype: Rabbit IgG; reactivity: Human,Mouse; observed MW: 90 kDa; calculated MW: 52260 MW.
Boster Bio Anti-Smad1 Rabbit Monoclonal Antibody catalog # M00728-1. Tested in WB, ICC/IF applications. This antibody reacts with Human, Mouse.
Key elements and design rationale
- Target: SMAD1 — Mothers against decapentaplegic homolog 1
- Antibody format: Host: Rabbit; Clonality: Monoclonal; Clone: Clone: CAC-19; Isotype: Rabbit IgG
- Species reactivity: Human,Mouse
- Molecular weight guidance: Observed: 90 kDa; Calculated: 52260 MW
Biological background
Protein function (datasheet): Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD1 is a receptor-regulated SMAD (R-SMAD). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. May act synergistically with SMAD4 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. .
Cellular localization (datasheet): Cytoplasm. Nucleus. Cytoplasmic in the absence of ligand. Migrates to the nucleus when complexed with SMAD4. Co-localizes with LEMD3 at the nucleus inner membrane.
Tissue details (datasheet): Ubiquitous. Highest expression seen in the heart and skeletal muscle.
Research relevance and current trends
- Commonly studied in contexts related to Growth Factors,Metabolism,Metabolism Processes,Nuclear Signaling,Nuclear Signaling Pathways,Pathways and Processes,Response To Hypoxia,Signal Transduction,Signaling Pathway,Stem Cells,TGF Beta.
- Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
- Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).
Common research applications
- Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
- Immunofluorescence / ICC: Visualize subcellular localization and co-localization patterns; consider fixation/permeabilization compatibility and controls.
Notes for experimental interpretation
- Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
- Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.
As a monoclonal antibody, this reagent is expected to recognize a defined epitope, which can support consistency across lots when epitope accessibility is preserved.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
